<a href="https://laohu8.com/S/COGT">Cogent Biosciences</a> Inc. Announces Positive Results from SUMMIT Trial, Plans NDA Submission for Bezuclastinib by End of 2025
Cogent Biosciences Inc. announced on July 7, 2025, that it has achieved positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in patients with non-advanced systemic mastocytosis. These results demonstrate clinically meaningful improvements across primary and secondary endpoints, strengthening the company's plan to submit a new drug application to the U.S. FDA by the end of 2025. The SUMMIT trial results will be detailed at a major medical conference later this year. Additionally, Cogent Biosciences is on track to release top-line results for its ongoing PEAK and APEX trials in the latter half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-155811), on July 07, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。